Diabetes Associated Ophthalmic Treatment Market (By Application: Diabetic Retinopathy, Diabetic Macular Edema, Cataracts, Glaucoma, Eye Allergy And Infection, Diabetic Associated Macular Degeneration, Uveitis, and Others; By Type: Drugs and Devices; By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers, and Others) - Global Industry Analysis, Market Size, Opportunities and Forecast 2021-2028

Category : Healthcare and Pharmaceuticals | Delivery Format: PDF | Status: Published | Pages : 250

CHAPTER 1. Industry Overview of Diabetes Associated Ophthalmic Treatment

1.1. Definition and Scope 

1.1.1. Definition of Diabetes Associated Ophthalmic Treatment

1.1.2. Market Segmentation

1.1.3. Years Considered for the Study

1.1.4. Assumptions and Acronyms Used

1.1.4.1. Market Assumptions and Market Forecast

1.1.4.2. Acronyms Used in Global Diabetes Associated Ophthalmic Treatment market

1.2. Summary

1.2.1. Executive Summary 

1.2.2. Diabetes Associated Ophthalmic Treatment By Application

1.2.3. Diabetes Associated Ophthalmic Treatment By Type

1.2.4. Diabetes Associated Ophthalmic Treatment By End-User

1.2.5. Diabetes Associated Ophthalmic Treatment by Regions


CHAPTER 2. Research Approach

2.1. Methodology 

2.1.1. Research Programs

2.1.2. Market Size Estimation

2.1.3. Market Breakdown and Data Triangulation

2.2. Data Source

2.2.1. Secondary Sources

2.2.2. Primary Sources


CHAPTER 3. Market Dynamics And Competition Analysis

3.1. Market Drivers

3.1.1. Driver 1

3.1.2. Driver 2

3.2. Restraints and Challenges

3.2.1. Restrain 1

3.2.2. Restrain 2

3.3. Growth Opportunities

3.3.1. Opportunity 1

3.3.2. Opportunity 2 

3.4. Porter’s Five Forces Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of Substitute

3.4.4. Threat of New Entrants

3.4.5. Degree of Competition

3.5. Market Concentration Ratio and Market Maturity Analysis of Diabetes Associated Ophthalmic Treatment Market

3.5.1. Go To Market Strategy

3.5.1.1. Introduction

3.5.1.2. Growth

3.5.1.3. Maturity

3.5.1.4. Saturation

3.5.1.5. Possible Development

3.6. Technological Roadmap for Diabetes Associated Ophthalmic Treatment Market

3.7. Value Chain Analysis

3.7.1. List of Key Manufacturers 

3.7.2. List of Customers

3.7.3. Level of Diabetic Macular Edema

3.8. Regulatory Compliance

3.9. Competitive Landscape, 2019

3.9.1. Player Positioning Analysis

3.9.2. Key Strategies Adopted By Leading Players


CHAPTER 4. Diabetes Associated Ophthalmic Treatment By Application

4.1. Introduction

4.2. Diabetes Associated Ophthalmic Treatment Revenue By Application

4.2.1. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast, By Application, 2017-2028

4.2.2. Diabetic Retinopathy

4.2.2.1. Diabetic Retinopathy Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

4.2.3. Diabetic Macular Edema

4.2.3.1. Diabetic Macular Edema Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

4.2.4. Glaucoma

4.2.4.1. Glaucoma Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

4.2.5. Cataract

4.2.5.1. Cataract Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

4.2.6. Eye Allergy & Infection

4.2.6.1. Eye Allergy & Infection Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

4.2.7. Diabetic Associated Macular Degeneration

4.2.7.1. Diabetic Associated Macular Degeneration Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

4.2.8. Uveitis

4.2.8.1. Uveitis Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

4.2.9. Others

4.2.9.1. Others Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028


CHAPTER 5. Diabetes Associated Ophthalmic Treatment By Type

5.1. Introduction

5.2. Diabetes Associated Ophthalmic Treatment Revenue By Type

5.2.1. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast, By Type, 2017-2028

5.2.2. Drugs

5.2.2.1. Drugs Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

5.2.3. Devices

5.2.3.1. Devices Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028


CHAPTER 6. Diabetes Associated Ophthalmic Treatment Market By End-User 

6.1. Introduction

6.2. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) By End-User

6.2.1. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

6.2.2. Ophthalmic Clinics

6.2.2.1. Ophthalmic Clinics Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

6.2.3. Hospitals

6.2.3.1. Hospitals Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

6.2.4. Ambulatory Surgical Centers

6.2.4.1. Ambulatory Surgical Centers Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028

6.2.5. Others

6.2.5.1. Others Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028


CHAPTER 7. North America Diabetes Associated Ophthalmic Treatment Market By Country 

7.1. North America Diabetes Associated Ophthalmic Treatment Overview

7.2. U.S.

7.2.1. U.S. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

7.2.2. U.S. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

7.2.3. U.S. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

7.3. Canada

7.3.1. Canada Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

7.3.2. Canada Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

7.3.3. Canada Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

7.4. North America PEST Analysis


CHAPTER 8. Europe Diabetes Associated Ophthalmic Treatment Market By Country

8.1. Europe Diabetes Associated Ophthalmic Treatment Overview

8.2. U.K.

8.2.1. U.K. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

8.2.2. U.K. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

8.2.3. U.K. Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

8.3. Germany

8.3.1. Germany Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

8.3.2. Germany Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

8.3.3. Germany Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

8.4. France 

8.4.1. France Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

8.4.2. France Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

8.4.3. France Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

8.5. Spain

8.5.1. Spain Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

8.5.2. Spain Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

8.5.3. Spain Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

8.6. Rest of Europe

8.6.1. Rest of Europe Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

8.6.2. Rest of Europe Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

8.6.3. Rest of Europe Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

8.7. Europe PEST Analysis


CHAPTER 9. Asia Pacific Diabetes Associated Ophthalmic Treatment Market By Country

9.1. Asia Pacific Diabetes Associated Ophthalmic Treatment Overview

9.2. China

9.2.1. China Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

9.2.2. China Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

9.2.3. China Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

9.3. Japan

9.3.1. Japan Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

9.3.2. Japan Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

9.3.3. Japan Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

9.4. India

9.4.1. India Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

9.4.2. India Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

9.4.3. India Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

9.5. Australia

9.5.1. Australia Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

9.5.2. Australia Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

9.5.3. Australia Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

9.6. South Korea

9.6.1. South Korea Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

9.6.2. South Korea Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

9.6.3. South Korea Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

9.7. Rest of Asia-Pacific

9.7.1. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

9.7.2. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

9.7.3. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

9.8. Asia Pacific PEST Analysis


CHAPTER 10. Latin America Diabetes Associated Ophthalmic Treatment Market By Country

10.1. Latin America Diabetes Associated Ophthalmic Treatment Overview

10.2. Brazil

10.2.1. Brazil Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

10.2.2. Brazil Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

10.2.3. Brazil Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

10.3. Mexico

10.3.1. Mexico Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

10.3.2. Mexico Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

10.3.3. Mexico Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

10.4. Rest of Latin America

10.4.1. Rest of Latin America Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

10.4.2. Rest of Latin America Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

10.4.3. Rest of Latin America Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

10.5. Latin America PEST Analysis


CHAPTER 11. Middle East & Africa Diabetes Associated Ophthalmic Treatment Market By Country 

11.1. Middle East & Africa Diabetes Associated Ophthalmic Treatment Overview

11.2. GCC

11.2.1. GCC Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

11.2.2. GCC Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

11.3. South Africa

11.3.1. South Africa Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

11.3.2. South Africa Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

11.3.3. South Africa Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

11.4. Rest of Middle East & Africa

11.4.1. Rest of Middle East & Africa Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Application, 2017-2028

11.4.2. Rest of Middle East & Africa Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By Type, 2017-2028

11.4.3. Rest of Middle East & Africa Diabetes Associated Ophthalmic Treatment Revenue (US$ Bn) and Forecast By End-User, 2017-2028

11.5. Middle East & Africa PEST Analysis


CHAPTER 12. Player Analysis Of Diabetes Associated Ophthalmic Treatment

12.1. Diabetes Associated Ophthalmic Treatment Company Share Analysis

12.2. Competition Matrix

12.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment

12.2.2. New Product Launches and Product Enhancements

12.2.3. Mergers And Acquisition In Global Diabetes Associated Ophthalmic Treatment market

12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements


CHAPTER 13. COMPANY PROFILE

13.1. Alcon

13.1.1. Company Snapshot

13.1.2. Business Overview

13.1.3. Financial Overview

13.1.3.1. Revenue (US$ Bn), 2020

13.1.3.2. Alcon 2019 Diabetes Associated Ophthalmic Treatment Business Regional Distribution

13.1.4. Product/Service and Specification

13.1.5. Recent Developments & Business Strategy

13.1.6. Manufacturing Plant Footprint Analysis

13.2. Allergan

13.3. Abbott Medical Optics

13.4. Bausch Health

13.5. Bayer AG

13.6. Carl Zeiss Meditec

13.7. Ellex Medical Lasers Ltd.

13.8. F. Hoffmann-La Roche Ltd

13.9. Genentech, Inc.

13.10. Johnson & Johnson Services, Inc.

13.11. Lumenis

13.12. Novartis AG

13.13. Pfizer, Inc.

13.14. Quantel

13.15. Santen Pharmaceutical Co. Ltd.

13.16. Topcon Corp.

Cart Summary